Navigation Links
UCB Presents Long-Term CImzia Data in Crohn's Disease

Cimzia Maintained Long-term Response at Stable Doses, According to New Data Presented at Digestive Disease Week (DDW)

ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announced today that new data presented at Digestive Disease Week 2007 (DDW) demonstrated long-term response and remission in Crohn's disease patients treated with Cimzia (certolizumab pegol), the only Fc-free PEGylated, Fab' fragment anti-TNF.

The study, called PRECiSE 3 (P3), is a long-term open label continuation of the Phase III PRECiSE Program for CIMZIA(TM). Some of the study results presented at DDW are an interim analysis of a patient subgroup that responded continuously to CIMZIA(TM) during an 18-month period. These patients completed the PRECiSE 1 (P1) or PRECiSE 2 (P2) trials, enrolling in P3 at week 26. At week 80, the study showed that more than 85 percent of the patient subgroup who continuously received CIMZIA(TM) 400 mg subcutaneously every four weeks maintained clinical response, with nearly 74 percent of these patients achieving remission. (1) The extension study used the Harvey-Bradshaw Index (HBI)(a) to assess clinical response (defined as a reduction in HBI score of at least three points) and remission (HBI score less than or equal to four points).

Importantly, results reported from P3 indicated that CIMZIA(TM) was well- tolerated throughout the study. The percentage of patients experiencing injection-site reactions and injection-site pain was low (<2%, <1% respectively). (3)

"These study results show robust rates of clinical response and remission during an 18-month period in patients with Crohn's disease," said Stephen Hanauer, M.D., Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology and Nutrition, University of Chicago, and study co-author. "Also, CIMZIA(TM) dosing did not need to be increased over the course of the study."

"These results fortify UCB's commitment to obtai
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCB Presents Long Term CImzia Data Crohn Disease
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Md., Feb. 25 Adlyfe, a private company developing ... today that it has signed an agreement with Wyeth ... designed to measure levels of beta amyloid in the ... specific beta amyloid targets for use in facilitating the ...
... Many soldiers who experienced mild head trauma or a ... to the United States with headaches, according to a study ... of Neurology,s 61st Annual Meeting in Seattle, April 25 to ... 978 U.S. Army soldiers returning from Iraq or Afghanistan in ...
Cached Medicine Technology:Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay 2For Iraq Veterans, Headaches Continue After Traumatic Brain Injury 2
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected ... when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal ... by physicians at Wake Forest Baptist Medical Center. ... single-center experience with cytoreductive surgery and HIPEC, said ... of 20 years, worth of patient data shows ...
(Date:4/17/2014)... after they suffer a cardiac arrest outside of a ... according to new research conducted at St. Michael,s Hospital. ... cardiac arrest get adrenaline, which has been the drug ... Steve Lin, an emergency physician and trauma team leader ... long-term survival rates of patients who suffer a cardiac ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Specialty Health Care Distributor Appoints Longtime Cardinal Health Executive ... and DUBLIN, Ohio, June 8 Sarnova, the nation,s leading ... medical services and respiratory markets, announced today that it ... A former president with Cardinal Health, Inc., Mr. Struik, ...
... , COSTA MESA, Calif., June 8 Oxygen Biotherapeutics, Inc. ... signed a securities purchase agreement and commenced an offer to ... the company,s common stock that are issued in the transactions ... of 1933, as amended, and may not be offered or ...
... Schwade, M.D. executive director of the CyberKnife Center of Miami ( ... Ultimate Miami CEO,s by the South Florida Business Journal. , , ... ten winners chosen as successful Miami businessmen who are among the upper ... CEO award winners include the following people: , , ...
... family-building benefits for its employees , , WOONSOCKET, R.I., ... is proud to announce it has been named one of ... for offering superior family-building benefits, such as health insurance coverage ... paid and unpaid leave for birth and adoptions. CVS ...
... June 8 On June 7th, Little Hearts, Inc. held ... One of the support services they offer is their "Picture ... kids ranging in age from infant to 50 of all ... (52), PA, TGA, TOF and Tricuspid Atresia. "HOPE" is shared ...
... to sleep deficit, researchers warn , MONDAY, June 8 (HealthDay ... fatigue probably signaled it was time to go to sleep. ... Housewives are more influential in determining bedtimes -- and ... a new study says. , In the study, researchers looked ...
Cached Medicine News:Health News:Sarnova Names Hank Struik Chief Executive Officer 2Health News:Sarnova Names Hank Struik Chief Executive Officer 3Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 2Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 3Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 2Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 3Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2Health News:Glowing TV Screens Keeping Americans Up at Night 2
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
... a solid phase two-site enzyme immunoassay. ... technique in which two monoclonal antibodies are ... human insulin molecule. During incubation, insulin ... antibodies and anti-insulin antibodies bound to the ...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
... an integral part of the enzymatic cascade ... as well as the degradation of Bradykinin. ... is primarily located in endothelial cells. ACE ... for sarcoidosis and myocardial infarction but is ...
Medicine Products: